Symposium

Visualizing the Future: Advances in IL-23-Targeted Therapies in the Treatment of IBD

Launch Date
05/19/2024 at 06:30 pm EST
Credit Amount
1.5
Credit Expires
05/19/2024

Faculty

Miguel Regueiro, MD
Moderator
Chief, Digestive Disease Institute
Professor in the Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH
Miguel Regueiro, MD
Moderator

Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.

Jessica R. Allegretti, MD, MPH, FACG, AGAF
Medical Director, Infusion Services
Director, Crohn's and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Angelina E. Collins, MSN, ANP-BC
Board Certified Nurse Practitioner
Inflammatory Bowel Disease Center
UC San Diego Health
La Jolla, CA
Edward V. Loftus, Jr., MD
Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine and Science
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Mayo Graduate School of Medicine
Rochester, MN
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize IL-23 by binding the Fab fragment to the P19 domain, the differences in Fc fragment structure may impact potency and clinical efficacy. Fc structure differences have been shown to impact binding of different agents to CD64 positive myelocytes, a main source of IL-23 in active IBD.

In this CME Outfitters symposium, expert faculty will review the role of the IL-23/Th-17 pathway in the pathogenesis of IBD and utilize animated 3-D models to illustrate differences in agents in the anti-IL-23 class that may have potential therapeutic implications. Learners will be guided through an evaluation of the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in IBD treatment, as well as the clinical evidence supporting the benefits of these IBD treatment features.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Evaluate the role of various pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
  • Identify the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
  • Assess the potential clinical implications of the ability of anti-IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23-producing cells

Financial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies.

Target Audience

Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), and nurses

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

PAs (AAPA) 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 01/25/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Regueiro reports the following financial relationships:

Advisory Board: AbbVie Inc; ALFASIGMA, S.p.A; Allergan, Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Labs; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; Target PharmaSolutions, Inc.; and UCB, Inc.

Consultant: AbbVie Inc; ALFASIGMA, S.p.A; Allergan, Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Labs; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; Target PharmaSolutions, Inc.; and UCB, Inc.

Grants: AbbVie Inc.; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Other financial or material support:
CME Companies: CME Outfitters; Cornerstones of Care; GI Health Foundation; HMP Global; iMedX; Medscape; MJH Life Sciences; MD Education; Remedy; and WebMD

Dr. Allegretti reports the following financial relationships:

Consultant: AbbVie Inc.; Adiso Therapeutics; Bristol Myers Squibb Company; Ferring Pharmaceuticals; Finch Therapeutics; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.; Roivant Sciences; and Seres Therapeutics

Research Support: Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc.

Speakers Bureau: Abbvie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.

Ms. Collins reports the following financial relationships:

Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.

Consultant: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Lilly; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Loftus reports the following financial relationships:

Advisory Board: Lilly and Morphic Therapeutic, Inc.

Consultant: AbbVie Inc.; Alvotech; Amgen Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma Inc.; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celltrion, Inc.; Fresenius Kabi; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Gossamer Bio; Iterative Health; Janssen Pharmaceuticals, Inc.; Ono Pharma USA, Inc.; Protagonist Therapeutics Inc.; Sun. Pharma; Surrozen; Takeda Pharmaceuticals U.S.A.; TR1X Bio; and UCB, Inc.

Grants: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; Celgene Corporation/Receptos, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; Theravance Biopharma; and UCB, Inc.

Stock Shareholder (directly purchased): Exact Sciences Corporation

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
John Jones, PharmD (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MM-137-051924-01

Visualizing the Future: Advances in IL-23-Targeted Therapies in the Treatment of IBD
Event Date: 05/19/2024 at 06:30 pm EST
Begin